Leukemia
Phase I
Accepting Patients
nct/study# NCT03915379 / JNJ-67571244-AML-1001
A Phase 1, First-In-Human, Dose Escalation Study Of JNJ-67571244 (Bispecific Antibody Targeting CD33 And CD3) In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT04075747 / JZP025-101
V-FAST: A Phase 1b Master Trial To Investigate CPX-351 Combined With Various Targeted Agents In Subjects With Previously Untreated Acute Myeloid Leukemia
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT03589326 / PONATINIB-3001
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered In Combination With Reduced-Intensity Chemotherapy, In Patients With Actively Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Learn More
Leukemia
Phase II
Active
nct/study# NA / BST004
A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome?
Learn More
Leukemia
Phase II
Active
nct/study# NA / SY-1425-202
Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen.
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT02631070 / ACE-536-MDS-002
A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions
Learn More
